GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (MEX:TXG) » Definitions » Cash Ratio

10x Genomics (MEX:TXG) Cash Ratio : 3.28 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is 10x Genomics Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. 10x Genomics's Cash Ratio for the quarter that ended in Sep. 2024 was 3.28.

10x Genomics has a Cash Ratio of 3.28. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for 10x Genomics's Cash Ratio or its related term are showing as below:

MEX:TXG' s Cash Ratio Range Over the Past 10 Years
Min: 1.3   Med: 3.86   Max: 8.86
Current: 3.28

During the past 7 years, 10x Genomics's highest Cash Ratio was 8.86. The lowest was 1.30. And the median was 3.86.

MEX:TXG's Cash Ratio is ranked better than
88.67% of 662 companies
in the Healthcare Providers & Services industry
Industry Median: 0.56 vs MEX:TXG: 3.28

10x Genomics Cash Ratio Historical Data

The historical data trend for 10x Genomics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

10x Genomics Cash Ratio Chart

10x Genomics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial 6.73 5.62 5.32 3.28 3.06

10x Genomics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.41 3.06 3.42 3.42 3.28

Competitive Comparison of 10x Genomics's Cash Ratio

For the Health Information Services subindustry, 10x Genomics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


10x Genomics's Cash Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where 10x Genomics's Cash Ratio falls into.



10x Genomics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

10x Genomics's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=6597.805/2158.479
=3.06

10x Genomics's Cash Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash Ratio (Q: Sep. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=7839.87/2387.154
=3.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


10x Genomics  (MEX:TXG) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


10x Genomics Cash Ratio Related Terms

Thank you for viewing the detailed overview of 10x Genomics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


10x Genomics Business Description

Traded in Other Exchanges
Address
6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.